Canadian cannabis company Tilray entered a global supply and distribution agreement with Novartis' generic drug business Sandoz.
Under the deal, Tilray and Sandoz will supply nonsmokable and noncombustible medical cannabis products where they are legal. In addition, the two companies may co-brand certain products and develop new ones.
"This agreement represents a major milestone in the movement to provide access to safe, GMP-certified medical cannabis to patients in need across the world," said Tilray CEO Brendan Kennedy.
The agreement marks the first of its kind for medical marijuana and a major milestone for the pharma industry, STAT reports.